Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities

• Main Authors: Matthias Shona Roost (Author), Henrike Potthast (Author), Chantal Walther (Author), Alfredo García-Arieta (Author), Ivana Abalos (Author), Eduardo Agostinho Freitas Fernandes (Author), Gustavo Mendes Lima Santos (Author), Zulema Rodríguez Martínez (Author), Andrew Tam (Author), Clare Rodrigues (Author), Diego Alejandro Gutierrez Triana (Author), Erwin Guzmán Aurela (Author), Nayive Rodríguez Rodríguez (Author), Sang Aeh Park (Author), Jayoung Kim (Author), Rami Kariv (Author), Milly Divinsky (Author), Ben Jones (Author), Ryosuke Kuribayashi (Author), Aya Myoenzono (Author), Miho Kasuga (Author), Joy van Oudtshoorn (Author), Jo-Feng Chi (Author), Wen-Yi Hung (Author), Li-Feng Hsu (Author), Christopher Crane (Author), Tony Jarman (Author), April Braddy (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This article describes an overview of waivers of in vivo bioequivalence studies for additional strengths in the context of the registration of modified release generic products and is a follow-up to the recent publication for the immediate release solid oral dosage forms. The current paper is based...